Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | CDK1 | P06493 | 1/20 | 0.32 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.32 |
| ▸ | MGMT | P16455 | 1/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.32 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18788389 | 0.92 | PDE2A (0.32) | PDE2A | |
| SCHEMBL18788387 | 0.87 | PDE2A (0.31) | PDE2A | |
| SCHEMBL19778888 | 0.78 | — | — | |
| SCHEMBL19779077 | 0.78 | — | — | |
| SCHEMBL18788255 | 0.77 | TP53 (0.31) | — | |
| SCHEMBL18787327 | 0.76 | BCHE (0.32) | — | |
| SCHEMBL18787315 | 0.74 | PDE2A (0.52) | PDE2A | |
| SCHEMBL12253818 | 0.73 | PDE2A (0.37) | PDE2ACDK1CCNB1MGMTCCNA2 | |
| SCHEMBL20404119 | 0.71 | PDE2A (0.42) | PDE2ACDK1CCNB1MGMTCCNA2 | |
| SCHEMBL13648874 | 0.70 | PDE2A (0.44) | PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10941177-B2 | 2′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20190016749-A1 | 2'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2019-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190016749-A1 | 2'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, SLC29A1, RNMT | PDE2A 507/4885CDK1 443/4885CCNB1 1109/4885 |
| US-10941177-B2 | 2′-substituted carba-nucleoside analogs for antiviral treatment | PNP, RNMT, SLC29A1 | PDE2A 491/4885CDK1 448/4885CCNB1 1181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.